A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin‐Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti‐Inflammatory Activities

Abstract

Purpose. Although doxorubicin chemotherapeutic drug is commonly used to treat various solid and hematological tumors, its clinical use is restricted because of its adverse effects on the normal cells/tissues, especially cardiotoxicity. The use of resveratrol may mitigate the doxorubicin-induced cardiotoxic effects. For this aim, we systematically reviewed the potential chemoprotective effects of resveratrol against the doxorubicin-induced cardiotoxicity. Methods. In the current study, a systematic search was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for the identification of all relevant studies on “the role of resveratrol on doxorubicin-induced cardiotoxicity” in the electronic databases of Web of Science, PubMed, and Scopus up to March 2021 using search terms in their titles and abstracts. Two hundred and eighteen articles were screened in accordance with a predefined set of inclusion and exclusion criteria. Finally, 33 eligible articles were included in this systematic review. Results. The in vitro and in vivo findings demonstrated a decreased cell survival, increased mortality, decreased heart weight, and increased ascites in the doxorubicin-treated groups compared to the control groups. The combined treatment of resveratrol and doxorubicin showed an opposite pattern than the doxorubicin-treated groups alone. Furthermore, this chemotherapeutic agent induced the biochemical and histopathological changes on the cardiac cells/tissue; however, the results (for most of the cases) revealed that these alterations induced by doxorubicin were reversed near to normal levels (control groups) by resveratrol coadministration. Conclusion. The results of this systematic review stated that coadministration of resveratrol alleviates the doxorubicin-induced cardiotoxicity. Resveratrol exerts these chemoprotective effects through several main mechanisms of antioxidant, antiapoptosis, and anti-inflammatory.

Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity

“…Isorhapontigenin, a new derivative of stilbene, alleviated CMA and cardiac atrophy caused by DOX, which is associated with the upregulation of yes-associated protein 1 expression (31). Resveratrol (3,5,4 ′ -trihydroxy-trans-stilbene, RES), a natural polyphenol which can be found mainly in grapes, red wine, soy, and peanuts, has been well studied in DIC protection (152). Earlier, Zhang et al found that RES prevented DOXinduced HW, BW, HW/BW ratio reduction, and cardiotoxicity via sirtuin 1(SIRT1)-p53 pathway (153).…”

l-Carnitine Mitigates Trazadone Induced Rat Cardiotoxicity Mediated via Modulation of Autophagy and Oxidative Stress

“…Several studies found that different dosages of LC, such as 150 and 300 mg/kg BW/day, had a protective impact on cardiomyocytes. Cardiotoxicity pathogenic alterations such necrotic muscle fibers and large inflammatory cellular infiltrations were reduced by LC [ 14 , 15 ]. LC + TRZ ( l -carnitine and TRZ) co-treated group Rats received TRZ (20 mg/kg/day) along with l -carnitine (200 mg/kg/day) for 28 days via oral gavage.…”

“…Several studies found that different dosages of LC, such as 150 and 300 mg/kg BW/day, had a protective impact on cardiomyocytes. Cardiotoxicity pathogenic alterations such necrotic muscle fibers and large inflammatory cellular infiltrations were reduced by LC [14,15].…”

Biodegradable porous polymeric drug as a drug delivery system: alleviation of doxorubicin-induced cardiotoxicity via passive targeted release

“…Previous studies showed that ROS generated by DOX caused cardiac injury and cardiomyocyte apoptosis. 42,43 We detected ROS levels in H9C2 cells by DCFH-DA staining to further investigate the effect of Fc-Ma-DOX treatment on DOX-induced cardiotoxicity in vitro. The H9C2 cells were plated in 6-well culture plates at a density of 6 × 104 cells per mL and then treated with free DOX (5 mg mL −1 ), Fc-Ma (5 mg mL −1 ) and Fc-Ma-DOX (at a DOX equivalent dose of 5 mg mL −1 ) for 24 hours, as shown in Fig.…”